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Abstract
Background: Advances in genetic and genomic research have introduced challenges in obtaining informed
consent for research in low and middle-income settings. However, there are only few studies that have explored
challenges in obtaining informed consent in genetic and genomic research in Africa and none in South Africa. To
start filling this gap, we conducted an empirical study to investigate the efficacy of informed consent procedures
for an H3Africa genomic study on Rheumatic Heart Disease (RHDGen) at the University of Cape Town in South
Africa. The main aim of the study was to understand ethical challenges in obtaining informed consent in the
RHDGen study.
Methods: We used a qualitative study methodology involving in-depth interviews and participant observations.
Our study participants were RHDGen cases (patients), healthy controls and research staff involved in the recruitment
of RHDGen cases and controls. In total, we conducted 32 in-depth interviews with RHDGen cases and controls, 2
in-depth interviews with research staff and 57 direct observations of the consent procedures of RHDGen cases
and controls. The interviews were conducted in English, audio-recorded and transcribed verbatim. Data were
analyzed using thematic content analysis. The study was conducted in 3 sites within Cape Town, South Africa.
Results: Most healthy controls joined the RHDGen study in order to be screened for rheumatic heart disease
(diagnostic misconception). A majority of RHDGen cases decided to join the RHDGen study because of
therapeutic misconception.
Conclusion: The ethical challenges that impacted on obtaining informed consent in the RHDGen study were
complex. In this study, the main challenges were diagnostic misconception among RHDGen controls and
therapeutic misconception among RHDGen cases.
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Background
Informed consent is paramount for the ethical conduct
of research [1–11]. However, empirical research shows
that obtaining genuine informed consent in biomedical
research is difficult in practice in both high and resource
limited settings [1]. In addition, advances in genetic and
genomic research have introduced new challenges in
obtaining informed consent in research practice [12].
Some of the new ethical challenges include granting
broad consent for use of samples and data in future re-
search [13–17]; the difficulty in explaining to potential
research participants the sharing of data and samples
with researchers who were not part of the original study
in which samples and data were collected; the challenge
of returning incidental or unrelated findings that were
not part of the original research project to research par-
ticipants [18–22]; and the difficulty in explaining risks
not only to individual genomic research participants but
also to their families, communities and even ethnic
groups in cases where members share the same genetic
mutation associated with increased risk of stigmatization
[15–22].
So far, there are few studies that have explored chal-
lenges in obtaining informed consent for genetic and
genomic research in Africa [12–19]. Specific ethical
challenges in informed consent that have been previ-
ously identified in African genomic research include
the difficulty in explaining scientific methods and con-
cepts such as “gene”, “genetics”, “genomics”, “DNA”,
“genetic database” and “data release” in local languages
during the consent process; the conduct of research in
emergency situations which make standard consent
processes impracticable especially where patients or
their guardians are under stress; therapeutic miscon-
ception among research participants who are recruited
in clinical settings and who have the widespread con-
ception that research studies result in clinical benefit;
the trust that research participants have in medical doc-
tors who are also researchers [15–19]; and the possible
risk of stigma or exploitation of study communities.
There is also a regulatory gap and limited legal and eth-
ical guidance available in Africa to support a transition
from specific consent to broad consent models [23].
These ethical challenges are frequently compounded by
low literacy, poverty, socio-cultural barriers and inef-
fective regulatory mechanisms in low and middle in-
come countries.
In addition, none of the published papers specifically
consider the implications of recruiting healthy controls
for genomic research in Africa generally and in South
Africa specifically. Interestingly, there is virtually no
work that has been done in South Africa on ethical
challenges in obtaining informed consent for genomic
research in general and the implications of recruiting
healthy controls for genomic research in particular. To
start filling this gap, we conducted an empirical study to
investigate the efficacy of the informed consent proce-
dures for a genomic study on Rheumatic Heart Disease
that is currently being conducted in the Department of
Medicine at the University of Cape Town in South
Africa. The main aim of the study was to understand
ethical challenges in obtaining informed consent in
the RHDGen study.
Background of the genomics of rheumatic heart disease
network (RHDGen) study
The RHDGen Study is one of the genomic research pro-
jects funded by the Wellcome Trust under the H3Africa
Consortium. Rheumatic Heart Disease (RHD) is a
chronic heart condition that is caused by Rheumatic
Fever (RF). RF is caused by a bacterium called Strepto-
coccus pyogenes that make some people have a sore
throat. While some people get better from this infec-
tion, others develop rheumatic heart disease. However,
the infection can be prevented from developing into
rheumatic heart disease by taking antibiotics such as
penicillin [24–26]. Currently, RHD remains the most
common cardiovascular disease in young people under
the age of 25 worldwide and it manifests itself with
heart failure, stroke, infective endocarditis and
pregnancy-related complications [27]. Whilst scientists
do not understand why some people with the infection
develop RHD while others do not develop the disease,
it is likely that genetics is a contributing factor [28].
The RHDGen study is recruiting 2500 adult patients
(cases) with echocardiographically-confirmed RHD
and it will compare their data with that of 3500 non-
affected individuals (healthy population controls) from
8 sub-Saharan African countries in order to identify
genetic factors of risk. The eight countries involved in
the RHDGen network are Kenya, Mozambique,
Namibia, Nigeria, South Africa, Sudan, Uganda and
Zambia. Written informed consent is obtained from
both prospective RHDGen cases and controls before
their participation in the study. RHDGen controls who
are found to have cardiac problems during the screen-
ing procedures into the RHDGen research project are
referred to Cardiac Clinics for medical attention. This
study on ethical challenges in obtaining informed con-
sent in the RHDGen study was nested in the RHDGen
study in South Africa specifically in the Western Cape
where both RHD cases and controls were being re-
cruited. For clarity in this paper, participants recruited
for the RHDGen study will be referred to as ‘cases and
controls recruited in the RHDGen study’. Participants
recruited for the qualitative study described in this
paper will be referred to as ‘participants for the re-
search study’, or “participants”.
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Methods
Study design
The study used a cross-sectional study design to collect
data from research participants. This design was appro-
priate for the study because data was collected from re-
search participants at one point in time thereby allowing
the acquisition of data in an open, flexible and inductive
manner. Since the main research question was to
understand ethical challenges in obtaining informed
consent in genomic research, the study was exploratory
and descriptive in nature.
Data collection methods, sampling and recruitment of
study participants
A combination of two qualitative research methods –
in-depth interviews (IDIs) and participant observations
(POs) – were employed in the study. The qualitative
study approach employed in this study allowed the
researchers to derive in-depth information from study
participants.
Before conducting each IDI, individual written in-
formed consent was obtained from each of the respon-
dents and a demographic data form was administered
to document respondents’ age, sex, highest education
achieved, occupation, religion, first language, the loca-
tion where the respondent was living, the type of
respondent and the time since the study participant
was recruited into the RHDGen research project. These
demographic data were used in the analysis process of
the interviews to compare responses from different
study participants based on their demographic informa-
tion Semi-structured interview guides were used to
guide the interviews with cases and controls recruited
into the RHDGen research project and research staff in
order to get in-depth knowledge and experience on the
consent process. The interview guides had sets of open-
ended questions and the questions were formulated
using the study objectives and they were being revised
as the data collection progressed.
The IDIs with cases in the Cardiac Clinic of the
Groote Schuur Hospital and with controls at the Van-
guard Community Health Centre and the Heideveld
Community as well as with research staff were con-
ducted by one researcher (FM). The IDIs were con-
ducted in English and consent was obtained for audio
recording. Audio-recordings were transcribed verbatim.
Notes were taken and observations were recorded at
each interview. All interviews were conducted on the
day of enrolment in the RHDGen study.
Both male and female cases and controls recruited
into the RHDGen research project were included in this
study. For the RHDGen cases, the IDIs were conducted
in the recruitment room located in the Cardiac Clinic of
the Groote Schuur Hospital. Twelve (12) IDIs were
conducted there with RHDGen cases. For RHDGen con-
trols, IDIs were conducted either in the front seat of the
van which was used for recruitment at the Vanguard
Community Health Centre and the Heideveld Commu-
nity or in the meeting room of the Clinical Research
Centre in the Old Main Building of the Groote Schuur
Hospital. Twenty (20) IDIs were conducted with
RHDGen controls at the Vanguard Community Health
Centre (9), Heideveld Community (5) and the Clinical
Research Centre in the Old Main Building of the Groote
Schuur Hospital (6). In total, 34 IDIs were conducted
with RHDGen cases and controls.
The study also targeted research nurses who were re-
sponsible for consenting potential RHDGen cases and
controls. The research nurses were scheduled for IDIs
at the time of their convenience. Two (2) IDIs were
conducted with research nurses involved in the con-
senting and recruitment of RHDGen cases and con-
trols. Both IDIs with research nurses were conducted
by the researcher.
In addition to in-depth interviews, we also conducted
a large number of participant observations for this pro-
ject. All POs were conducted by one of us. For the POs,
the research nurse administering the consent process
introduced the researcher orally before commencing
the RHDGen consent process. The researcher then
sought verbal consent from each potential study partici-
pant for his presence during the consenting process. All
study participants in the POs were given an informa-
tion leaflet to inform them about the study. During the
observations, the researcher took notes which were
typed up immediately after the observations. The infor-
mation obtained in the POs informed the topic guides
for IDIs with both RHDGen cases and controls as well
as research staff. Some of the POs were succeeded by
IDIs with both RHDGen cases and controls.
The POs with RHDGen cases and controls were con-
ducted at the same venues where they were recruited
into the RHDGen research project while the IDIs with
research staff were conducted at the Clinical Research
Centre in the Old Main Building of the Groote Schuur
Hospital.
Data were collected from RHDGen cases and controls
as well as research staff for a period of 5 months from
July to November 2014.
In total, 91 study participants were recruited into
the study. Thirty-four (34) participants took part in
the in-depth interviews while 57 participants took part
in the observations.
Study setting
As highlighted above, participants for this study were re-
cruited in the Cardiac Clinic and the Clinical Research
Centre of the Groote Schuur Hospital as well as the
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Vanguard Community Health Centre and the Heideveld
Community within Cape Town in South Africa. The
study enrolled RHDGen cases and controls as well
RHDGen research staff involved in recruiting RHDGen
cases and controls. The RHDGen cases were recruited
from the Cardiac Clinic at the Groote Schuur Hospital.
Controls for the RHDGen research project were re-
cruited at the Vanguard Community Health Centre in
Bonteheuwel, the Heideveld Community in the Cape
Flats and the Clinical Research Centre of the Groote
Schuur Hospital. All the controls for the RHDGen re-
search project were people who did not suffer from any
chronic diseases, including heart disease, at the time of
recruitment.
The study conducted observations of the consent
process and in-depth interviews with RHDGen cases
and controls across all these RHDGen recruitment sites.
The RHDGen staff were recruited and interviewed at the
Clinical Research Centre.
Participant observations of the consent process of
both RHDGen cases and controls were conducted in
the Cardiac Clinic and Clinical Research Centre at the
Groote Schuur Hospital, the Vanguard Community
Health Centre and the Heideveld Community.
Data processing and management
All interviews were conducted in English and recordings
were transcribed verbatim. Each transcript had a preamble
or summary of the interview which was informed by
the notes that were taken during the interviews. All
transcripts were imported into NVivo 10 for analysis.
Notes were taken during the POs and typed up imme-
diately after each PO. The written notes from the POs
were read thoroughly in order to understand the dy-
namics in the recruitment and consenting process of
the RHDGen cases and controls.
Data analysis
Thematic content analysis was used to analyze interview
data. The analysis was iterative and preliminary analysis
started immediately when the initial interviews were
transcribed. Two researchers were involved in the ana-
lysis and we used a progressive coding strategy where we
first assigned open codes to interesting or relevant text
excerpts. These codes were descriptive of the content of
the quotes. Once we had gone through a small number
of interviews and did not find any additional codes, we
looked at the list of open codes and started to develop a
hierarchical coding scheme, identifying what appeared as
overarching themes and codes underneath those. After
piloting and adapting that initial coding scheme, we
developed a final hierarchical coding scheme that was
applied to all the interviews in our dataset. The higher
hierarchical codes were grouped into main themes with
the lower nodes as their sub-themes. The transcripts
were re-coded using this new hierarchical coding
scheme. Memos were written for each hierarchical code.
We reviewed and discussed the quotes for each theme.
Data summaries were produced from the texts. The data
summaries comprised main themes and their sub-
themes as well as their quotes as examples from the
texts. We discussed the data summaries and from the
discussions, a charting framework was developed with
linkages to the data. The charts were produced for each
main theme and sub-theme. The charts were also com-
pared across all themes. Each chart was given a descriptive
account of each theme and had relevant quotes from the
study participants. The charts were used to develop a first
account of the empirical data, which we discussed. Sub-
sequent drafts re-examined the data and the charts,
and integrated emerging insights into the analysis.
Ethical considerations
Ethics approval for this study was obtained from the
Human Subjects Research Review Committee in the
Faculty of Health Sciences at the University of Cape
Town (FHS HREC 251–2014). Written consent was ob-
tained from each of the study participants prior to their
participation in the IDIs while verbal consent was ob-
tained from all the participants who participated in the
participant observations. Verbal consent was obtained
from the potential study participants to have the con-
sent process observed because there was no interaction
with the RHDGen cases and controls during the con-
sent process other than observing the consent process.
Individual written informed consent was sought from
each of the research nurses administering the consent
procedures once before the first participant observation
was conducted.
Results
Demographic characteristics of study participants
A total of 34 IDIs and 57 POs were conducted with
RHD cases and controls as well as RHDGen research
staff. Most study participants were females and aged
between 18 and 40. Table 1 below gives demographic
characteristics of the study participants.
Diagnostic misconception as a motivation for study
participation among RHDGen controls
In this paper, we focus our analysis on the factors that
motivated healthy people to participate in the genomics
research project we were concerned with. These partici-
pants described a variety of reasons to participate in
the study, including for instance altruism, trust and
familiarity with research staff. However, the most com-
mon motivation for study participation among the
RHDGen controls was diagnostic misconception.
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Unmet health care needs as a contribution to diagnostic
misconception among the RHDGen controls
One of the most often expressed motivators related to
curiosity about ‘seeing one’s heart’ beat on a monitor,
and finding out whether one’s heart was healthy.
The thing that motivated me was to know if I have a
heart disease and I wanted to see my heart beating too
(IDI # COV 02).
I was interested to know if I have a heart problem
and I am happy that I don’t have any heart problem
(IDI # COV 04).
Yes, it is helpful because people are able to know
whether they have a heart problem. For me I was
very happy when the doctor told me that I don’t
have any heart problem (IDI with study participant
# COC 21).
The consent process for this genomic study included
information about Rheumatic Heart Disease, which is
the disease that was studied in the genomic study. But
whilst it makes sense for the consent process for RHD
patients (recruited as ‘cases’) to be tied to the illness
that the genomic study focuses on, this focus appeared
confusing for control participants who were not ill with
heart disease.
What participants seemed to retain most strongly
about the study is that they were informed that they
would have heart scans and the doctor would be able to
tell them if they had any heart problems or conditions.
I just wanted to check my heart if I had a problem or
not (IDI # COV 01).
The main reason why people decided to come is
because of the screening for heart problems. We were
told you had those machines for screening people and
since most of us do not know whether we have heart
problems or not, it was necessary to come for the
screening (IDI # COH 30).
During participant observations, we found that many
participants approached research participation a bit like
they may approach an examination – with initial appre-
hension, and then full of joy and happiness after going
through the screening program and after being told that
they did not have rheumatic heart disease. Some came
out of the bus with their arms in the air, saying “I passed
the test!”
Many of the controls we interviewed referred to the
RHDGen study as a screening study, offering a free ser-
vice that is rarely available in their communities. For
instance,
I think the other reason is that this is a free service
and such free services are rarely found here. So,
I thought it was necessary to have the service
(IDI # COV 04).
We don’t have check-ups for heart problems here
and sometimes they don’t test our blood when we
are sick. So, with these free check-ups, I decided to come
(IDI # COV 10).







Of which Research Staff
(N = 2)
Percentages (100%)
Gender Male 10 4 6 0 29%
Female 24 8 14 2 71%
Age 18-40 21 9 11 1 62%
41-61 13 3 9 1 38%
First language Xhosa 17 9 8 0 50%
Afrikaans 14 3 10 1 41%
English 3 0 2 1 9%
Occupation Employed 23 10 11 2 68%
Not employed 11 2 9 0 32%
Religion Christian 26 6 14 2 76%
Muslim 6 3 4 0 18%
Non-religious 2 3 2 0 6%
Highest level of
education achieved
Primary 2 0 2 0 6%
Secondary 24 8 16 0 71%
Tertiary 8 4 2 2 23%
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The impression that the RHDGen study involved a
screening programme was reinforced in two important
ways: first, because recruitment took place in a van
that was equipped with ECG and ECHO machines,
and that carried colourful branding of the university,
the research group and the disease we work on. Study
participants were familiar with other screening activ-
ities that take place in these communities from time to
time – for breast cancer, HIV and TB for instance.
Such screening endeavours employ a similar van,
branded in a similar way, and so the assumption that
this genomic research project was also a screening
project seems logical. Thus,
I asked the sister to test me for TB and HIV too
because my brother was tested for TB by the same
people when they came to test people for TB and HIV
in our community last year. But the sister told me that
they are not testing people for TB and HIV this time.
Instead they are testing people for heart disease. So,
they tested me for the heart disease but the machine
did not find it. (IDI # COV 13).
Well I work for an organization that runs clinical
trials. So, it was quite interesting to be the participant
and decided to consent and to be informed about
this study. I came partly because I was quite keen
to have an ECHO and an ECG; for me, it was a
way of testing my heart to see if it was healthy …
(IDI # COC 20).
Community leader contributions to diagnostic
misconception among RHDGen controls
The impression that the RHDGen study involved screen-
ing was reinforced by the research groups’ reliance on
community leaders to identify research participants.
Particularly in one of the four recruitment sites, the
research team had built relationships with a community
leader who assured the team of safety and hosted the
team when recruiting – for instance, by making his
home available to the research nurse for blood collec-
tion. This community leader seemed eager to please
and ensure that the group reached target recruitment
numbers. In ensuring that enough people showed up on
the right date, he had apparently informed community
members that there was going to be a free screening
program on rheumatic heart disease by doctors from
Groote Schuur Hospital.
I was asked to come by our chairman. He announced two
days ago that doctors from the Groote Schuur Hospital
will come today and every Monday to screen people for
rheumatic heart disease. So, that is why I came today
(IDI # COH 26).
The community leader announced to everybody that
you would be coming to this community to check
people for rheumatic heart disease (IDI # COH 32).
An interesting contributory factor lending further sup-
port to the importance of the diagnostic misconception
in the RHDGen enrolment is that many controls also
described that they joined the RHDGen study because of
stories they had heard of people who had heart compli-
cations and died because of ignorance about the status
of their heart conditions, for instance,
Because another thing that made me get interested,
my sister in law died of a heart disease. She had a
heart problem and so that’s what interested me to
know if I have a heart problem. I was also scared of
passing away from such a disease (IDI # COV 02).
The doctor put something on my chest and I could see
my heart moving and he recorded everything on that
machine. After that, I went to the third room where I
could see the beating of my heart and the lady there
told me that I don’t have any heart problem and my
heart condition is fine. Obviously, I was happy to hear
that because I was worried about my heart since I feel
pain at the chest at times (IDI # COH 30).
Logistical contributions to diagnostic misconception
among RHDGen controls
One of the RHDGen research staff who participated in
the in-depth interviews noted that lack of understanding
due to language barriers might have contributed to the
misconception that the study was a screening program
for heart conditions. She also observed that some of the
RHDGen controls had already made up their mind to
have the screening before they went through the consent
process and that it was difficult for such controls to
understand that this was a research activity and not a
screening program. Thus she said:
Ok I think the first challenge is probably the language
barrier because I don’t speak Xhosa. And so, that’s a
big challenge to some patients, although they might
speak English but their English isn’t good. Another
challenge is some patients come when they have
already made up their mind to be screened for heart
conditions. So, even when you give them information
that this is research, they seem not to understand
(IDI # RS 02).
Evidence of therapeutic misconception as a motivation
for study participation among RHDGen cases
By contrast, when we examined the data from interviews
with RHD patients recruited as cases, we did not find
Masiye et al. BMC Medical Ethics  (2017) 18:12 Page 6 of 9
such strong evidence of a diagnostic misconception.
However, RHD patients linked their motivations to par-
ticipate more clearly to the condition under study, and to
the hope that this study could help in the identification of
new therapies for RHD. For instance, the RHDGen cases
described that the current drugs that are being given to
patients with rheumatic heart disease such as warfarin can
have devastating side effects and they felt that through the
RHDGen study, doctors and scientists would be able to
develop better drugs for the current RHD patients and
other patients in the future.
I think it will also help doctors to come up with new
and better medications for this disease because they
will understand what happens in the body when one
has the disease by studying the DNA. In such a way,
patients with rheumatic heart disease will be treated
better and other patients with this disease will not
have complications in the future (IDI # CWR 18).
Aah I think the issue of finding better drugs for people
who suffer from this disease is important (IDI # CWR 15).
As I said they may also develop better medicines to
treat the disease (IDI # CWR 18).
I joined because this study is useful. As I said it will
help in developing better treatment and prevention
for people with the sore throat, fever and those with
the disease (IDI # CWR 15).
While some RHDGen cases recruited in the Cardiac
Clinic at the Groote Schuur Hospital reported an ex-
pectation that the drugs that would be developed from
this study could help them in improving their own
health, other patients anticipated that they would derive
direct personal benefit in the form of better treatment
from the drugs that would be developed from the results
of the RHDGen study. The expectation to receive better
treatment because of their participation in the RHDGen
study has been described as ‘therapeutic misconception’
in the ethics literature. Therapeutic misconception de-
picts the hope that research participants may experience
when previous clinical treatments have failed to help
them adequately and hope to obtain better treatment by
participating in research [28].
Discussion
From the findings of this study, it is evident that the ma-
jority of RHDGen controls chose to participate in the
RHDGen study because they were motivated by know-
ledge about heart disease, heart conditions, blood pres-
sure, general health status and other medical conditions.
This specific challenge has been termed ‘diagnostic
misconception” in literature describing challenges in the
consent process for genomics research. It is a unique
challenge that arises in the context of genomics research
and similar studies that recruit thousands of healthy
participants in a study that is usually disease-specific,
using consent forms that are designed around the dis-
ease in question. The diagnostic misconception arises
when research participants do not appreciate the differ-
ence between research and diagnosis [20]. It has been
identified as an equivalent of therapeutic misconception in
the genetic research context [20]. According to literature,
diagnostic misconception occurs when potential research
participants consider research participation as an oppor-
tunity to be checked or diagnosed for diseases [22, 29]. In
some cases, participants may believe that they are being
enrolled in research in order to be checked for the disease
under study while in other cases, research participants
may believe that they are being enrolled in research in
order to receive individualized information about medical
diagnoses and future disease risks [20, 21, 30]. This is con-
trasted with therapeutic misconception that occurs in clin-
ical trials when research participants either misunderstand
or fail to appreciate the key differences between research
and clinical care [31–34]. Currently, there is not much em-
pirical data on diagnostic misconception in genetic studies
and none in genomic studies in Africa. Therefore, this
paper constitutes the first evidence of diagnostic miscon-
ception as an ethical challenge to genomic studies in
Africa.
One important reason that the diagnostic misconcep-
tion arose strongly in our study relates to the relatively
resource-limited backgrounds of many of our study par-
ticipants. Rheumatic Heart Disease is a poverty-related
condition that is more prevalent in poorer communities
with crowded housing [35]. Because of a scientific need to
closely match cases and controls in terms of ethnicity and
age, the research team recruited controls from communi-
ties attending the Vanguard Community Health Centre
and living in Heideveld. Both of these are resource-limited
communities with low average income, limited access to
healthcare services, and high rates of crime. In these com-
munities, the opportunity to benefit from what was per-
ceived to be a free healthcare service is significant and
important to study participants.
What also contributed to the diagnostic misconception
is that recruitment took place in a van that prominently
displayed public health messages relating to Rheumatic
Heart Disease and children’s health - a remnant of a pre-
vious research project by the group. This van is similar
to those used by other public health screening endeav-
ours, including for instance breast cancer, TB and HIV
screening. This similarity caused expectations that par-
ticipation in the project constituted undergoing a med-
ical examination for heart disease, rather than mere
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participation in a research project. The recruitment of
large numbers of healthy participants, who had not pre-
viously heard of rheumatic heart disease, further in-
creased the incidence of diagnostic misconception.
Conclusion
Based on the information which was obtained from
participant observations during the recruitment process
of both RHD cases and controls as well as in-depth in-
terviews with RHDGen cases, controls and research staff
involved in obtaining informed consent from research
participants, most RHDGen controls had beliefs related
to diagnostic misconception while RHDGen cases were
motivated by therapeutic misconception. The RHDGen
controls mistakenly considered the RHDGen study as
a free screening program for heart conditions while
RHDGen cases considered it as a drug trial for rheum-
atic heart disease. In order to avoid diagnostic miscon-
ception and therapeutic misconception in future
genomic studies, there is need for provision of adequate
information about research objectives and procedures
including anticipated benefits and risks to potential re-
search participants before obtaining their consent to
participate in genomic studies. There is also need to as-
sess potential research participants’ understanding or
comprehension about scientific terms and concepts used
in genomic research prior to enrolling them in genomic
studies. In addition, research staff who are involved in
recruiting potential research participants for genomic
studies must be creative during the recruitment process
and ensure that the studies are conducted properly with-
out compromising ethics. Consent processes must be
flexible enough to allow staff to adjust these to the spe-
cific recruitment context and ensure that potential re-
search participants make informed decisions. Moreover,
the design of consent forms and processes for genomic
research should not be based on checklists for consent
documents but they must be informed by experiences of
researchers and field staff working in communities
where the intended research projects are to be con-
ducted. For instance, the consent process for recruiting
potential research participants from communities that
are unsafe and insecure for research staff must be
informed by inputs from community leaders and re-
searchers who have experience in conducting research
in such communities. Furthermore, there is need to im-
prove communication with and education of community
partners who are involved in identifying potential re-
search participants for recruitment into research studies.
Research staff must involve both community partners
and potential research participants in sensitization ac-
tivities where they have to explain scientific terms and
concepts used in genomic research and allow them to
ask questions before approaching individuals to take
part in their genomic research projects. Such commu-
nity education should ideally involve all community
members. In communities where community advisory
boards (CABs) exist, CAB members should be involved
in communicating scientific terms and concepts in lay
terms to their fellow community members. In communi-
ties where CABs do not exist, it is important to establish
CABs to assist research staff in sensitization activities
and communicating information about genomics, DNA
and data sharing prior to approaching individual poten-
tial research participants to join genomic studies. Finally,
it is necessary to train research staff responsible for
recruiting research participants in the protocol and the
informed consent process before initiating genomic re-
search projects. After such protocol and informed con-
sent process training, research staff should conduct pre-
testing (piloting) of data collection tools and informed
consent documents among lay community members and
make appropriate corrections or revisions to the data
collection tools and informed consent documents before
implementing genomic studies.
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